ReWalk Robotics Reports Second Quarter 2015 Financial Results

YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq:RWLK) ("ReWalk" or "the Company") today announced its financial results for the three- and six-months ended June 30, 2015.

Highlights of and subsequent to the second quarter include:

• Total revenue was $610,000 compared to $500,000 during the second quarter of 2014;
   
• Placed 12 ReWalk systems during the second quarter of 2015 compared to 10 systems during the second quarter of 2014;
   
• Received positive coverage decisions on behalf of ReWalk's customers from two large private commercial insurers for the ReWalk Personal system;
   
• Increased ReWalk's commercial reimbursement pipeline to 59 fully completed pending insurance claims;
   
• Received approval for continuing education credit in 22 states for ReWalk's clinician training program from the Federation of State Boards on Physical Therapy; and
   
• Introduced ReWalk Personal 6.0, ReWalk's next generation device that offers the fastest walking speed, most natural gait and most precise fit of any exoskeleton on the market.

"Although second quarter growth was slower than we expected, demand generation in terms of qualified leads and completed filings for reimbursement grew substantially. We expanded and modified our training programs to more effectively qualify users and to better assist individuals in advancing their reimbursement applications," said Larry Jasinski, Chief Executive Officer.

"In July, we launched a significant new product, the ReWalk Personal 6.0, which offers many superior features over any product in the market or in clinical trials today. With its streamlined design, including elimination of the backpack, we expect it will increase the number of users and offer them a better walking experience," he added.  

 "We remain confident that the market opportunity and growth potential for ReWalk in our emerging industry is significant. And, that we will continue to expand our leadership position in wearable exoskeleton market for many years to come," Jasinski concluded.

Second Quarter 2015 Financial Results

Total revenue was $610,000 for the second quarter of 2015, up 22% compared with $500,000 in the second quarter of 2014. In the second quarter of 2015, 12 ReWalk systems were placed compared with 10 ReWalk systems placed in the prior year period.

Gross profit in the second quarter was $60,000 as compared to a gross loss of $225,000 for the second quarter of 2014 reflecting the positive impact of moving manufacturing operations to Sanmina in the second half of 2014.

Total operating expenses in the second quarter of 2015 were $5.9 million, versus $3.6 million in the second quarter of 2014, reflecting ReWalk's increased investment in sales and market development activities, including the roll-out of ReWalk Personal 6.0, building the reimbursement team and supporting processes, investing in research and development, and the cost of being a publicly-traded company.

Net loss was $5.8 million for the second quarter of 2015 versus $4.7 million for the same period last year. Non-GAAP net loss for the second quarter was $5.2 million compared with non-GAAP net loss of $3.7 million in the prior year quarter. 

A reconciliation of net loss to non-GAAP net loss is included at the end of this press release.

Six Months Ended June 30, 2015 Financial Results

Total revenues were $1.2 million for the six months ended June 30, 2015, up 32% compared with $945,000 during the six months ended June 30, 2014. In the 2015 six-month period, 25 ReWalk systems were placed compared to 16 ReWalk systems placed during the same period in 2014.

Gross profit was $93,000 for the six months ended June 30, 2015 as compared to a gross loss of $423,000 for the six months ended June 30, 2014 reflecting higher volume of sales in the 2015 period coupled with manufacturing economies of scale and the positive impact of moving manufacturing operations to Sanmina in the second half of 2014.

Total operating expenses were $11.5 million for the six months ended June 30, 2015 versus $6.4 million in the prior year period, reflecting increase of non-cash share-based compensation of $0.8 million, increased investment in sales and marketing, and research and development, and the cost of being a publicly-traded company.

Operating loss for the six months ended June 30, 2015, was $11.4 million compared with $6.9 million during the prior year period. 

Net loss for the six months ended June 30, 2015 was $11.5 million compared with $9.7 million during the six months ended June 30, 2014. Non-GAAP net loss was $10.3 million for the six months ended June 30, 2015, compared with non-GAAP net loss of $6.6 million for the same period last year.

Liquidity

As of June 30, 2015, ReWalk had $31.2 million in cash and cash equivalents.

Conference Call

ReWalk management will host its third quarter conference call as follows:

A telephone replay will be available shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode for the replay is 90065491. 

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk's mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.  For more information on the ReWalk systems, please visit http://www.rewalk.com.

Forward Looking Statements

This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "intends," "anticipate(s)," "look forward," "upcoming," "plan," "enables," "potentially," "entitles," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the underlying sales for the second quarter of 2015; future availability of reimbursement for ReWalk in Germany and the United States; and the successful and timely achievement of favorable coverage decisions for ReWalk by additional major insurers.  All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to the following: the market for medical exoskeletons is new and unproven, and important assumptions about the potential market for ReWalk's products may be inaccurate; the Company has a limited operating history upon which you can evaluate its business plan and prospects; if ReWalk is unable to expand its sales, marketing and training infrastructure, it may fail to increase its sales; the health benefits of ReWalk have not been substantiated by long-term clinical data, which could limit sales; the Company may fail to secure or retain adequate coverage or reimbursement for ReWalk by third-party payers; the Company depends on a single third-party to manufacture ReWalk and a limited number of third-party suppliers for certain components of ReWalk; the Company's future growth and operating results will depend on its ability to develop and commercialize new products and penetrate new markets; the Company operates in a competitive industry that is subject to rapid technological change, and the Company expects competition to increase; and the Company is subject to extensive governmental regulations relating to the manufacturing, labeling and marketing of its products. These and other risk factors are set forth in the Company's final Annual Report on Form 20-F for the year-ended December 31, 2014 filed with the Securities and Exchange Commission on February 27, 2015, and the Company's other reports filed from time to time with the Securities and Exchange Commission.  Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.  ReWalk does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of non-GAAP accounting measures, including non-GAAP net loss is helpful to its investors. These measures, which the Company refers to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three- and six-months ended June 30, 2015 and 2014, non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense and (ii) the revaluation of warrants to purchase convertible preferred shares.

Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash expenses, the Company believes that providing non-GAAP financial measures that exclude share-based compensation expense and non-cash financial (income) expenses allows for more meaningful comparisons between operating results from period to period. Each of the Company's non-GAAP financial measures is an important tool for financial and operational decision-making and for evaluating our own operating results over different periods of time. The non-GAAP financial data are not measures of the Company's financial performance under U.S. GAAP, and should not be considered as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company's industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies, and exclude expenses that may have a material impact on the Company's reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company's business and an important part of the compensation provided to its employees. The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP.  ReWalk urges investors to review the reconciliation of non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measures to evaluate the business.

(tables follow)